贝伐珠单抗联合紫杉醇治疗复发性卵巢癌90例安全性探索

Safety of bevacizumab combination with paclitaxel in the treatment of recurrent ovarian cancer in 90 cases

目的:探讨贝伐珠单抗联合紫杉醇治疗复发性卵巢癌的效果和安全性。方法:收治复发性卵巢癌患者90例,分为研究组和参照组。研究组采用贝伐珠单抗联合紫杉醇治疗,参照组采用紫杉醇联合洛铂化疗,比较两组治疗效果和安全性。结果:研究组临床总有效率和不良反应发生率均显著优于参照组(P<0.05)。讨论:贝伐珠单抗联合紫杉醇治疗复发性卵巢癌的效果显著,安全性高。

Objective：To explore the effect and safety- of bevacizumab combination with paclitaxel in the treatment of recurrent ovarian cancer.Methods：90 patients with recurrent ovarian cancer were selected and they were divided into the study group and the reference group.The study group was treated with bevacizumab combination with paclitaxel,and the control group was treated with paclitaxel combined chemotherapy with lobaplatin.We compared the treatment effect and safety- of two groups.Results：In the study group,the total clinical efficiency and the incidence of adverse reactions were significantly better than those of the reference group（P 〈 0.05）.Conclusion：The effect of bevacizumab combination with paclitaxel in the treatment of recurrent ovarian cancer was significant,and the safety- was high.